Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Free Cash Flow: 2020-2024

Historic Free Cash Flow for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to $38.0 million.

  • Monte Rosa Therapeutics' Free Cash Flow rose 566.40% to $99.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $145.0 million, marking a year-over-year increase of 330.98%. This contributed to the annual value of $38.0 million for FY2024, which is 160.48% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Free Cash Flow stood at $38.0 million for FY2024, which was up 160.48% from -$62.8 million recorded in FY2023.
  • Monte Rosa Therapeutics' Free Cash Flow's 5-year high stood at $38.0 million during FY2024, with a 5-year trough of -$105.4 million in FY2022.
  • Its 3-year average for Free Cash Flow is -$43.4 million, with a median of -$62.8 million in 2023.
  • Per our database at Business Quant, Monte Rosa Therapeutics' Free Cash Flow plummeted by 161.31% in 2021 and then soared by 160.48% in 2024.
  • Yearly analysis of 5 years shows Monte Rosa Therapeutics' Free Cash Flow stood at -$26.4 million in 2020, then slumped by 161.31% to -$69.1 million in 2021, then tumbled by 52.51% to -$105.4 million in 2022, then soared by 40.36% to -$62.8 million in 2023, then spiked by 160.48% to $38.0 million in 2024.